Amicus Therapeutics

  www.amicustherapeutics.com
  www.amicustherapeutics.com
Work in HR? Unlock Free Profile

Amicus Therapeutics Reviews

8 Reviews
4.1
8 Reviews
Rating Trends

Recommend to a friend
Approve of CEO
Amicus Therapeutics President, CEO and Director John F. Crowley
John F. Crowley
7 Ratings
  1.  

    Excellent learning environment

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - In-vivo Pharmacology Co-op  in  Cranbury, NJ
    Former Employee - In-vivo Pharmacology Co-op in Cranbury, NJ

    I worked at Amicus Therapeutics as an intern for less than a year

    Pros

    As a newbie co-op, this was a great place to learn a wide variety of technical skills in addition to gaining exposure to a healthy small pharma culture. As a small, growing company, the enthusiasm was palpable and was invaluable for me as a developing researcher.

    Cons

    An understandable consequence of starting at the bottom of the food chain was a lack of understanding the development strategies trickling down from the top.

    Advice to ManagementAdvice

    Stay hungry.

    Recommends
    Neutral Outlook
    Approves of CEO

Amicus Therapeutics Awards & Accolades

Something missing? Add an award
Best Places to Work in New Jersey (Small/Medium), Best Companies Group, 2009

Additional Info

Edit Profile
Website www.amicustherapeutics.com
Headquarters Cranbury, NJ
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (FOLD)
Industry Biotech & Pharmaceuticals
Revenue Less than $1 million (USD) per year

Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological "chaperones" which bind to a patient's own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative... More

Worked for Amicus Therapeutics? Contribute to the Community!